Home >Research Technology Management>Collaborative Project
The positive reputation of Institut Pasteur Korea and its technology in the international pharmaceutical community has led to collaborations with Sanofi, GSK and Servier. Also of significance, Institut Pasteur Korea entered the Korean market by establishing a privileged partnership with Green Cross. The formation of these collaborations is an important milestone for the development of further business relationships in the pharmaceutical arena.
Institut Pasteur Korea is actively establishing research collaborations with partners from local and international academia, research institutions, and industry.
Proprietary compounds representative of the entire Sanofi compound library are being shared for the first time outside of a consortium arrangement. Our research collaboration on Hepatitis B virus (HBV) that was initiated in 2011 is successfully moving forward with a variety of hit compounds. On April 5, 2013, we finalized a Master Collaboration Agreement with a signing ceremony at the joint symposium with Sanofi in France.
GSK in the UK is financing further development of Institut Pasteur Korea’s new anti-tuberculosis compound, which has an interesting mechanism of action specific for intracellular mycobacteria. In addition, we are continuing our collaboration with GSK under a EUFP7 consortium grant. This work, involving a GSK molecule identified as active in our propriety macrophage assay, has progressed from screening into hit to lead studies. A proposal was submitted to the open lab foundation (www.openlabfoundation.org) to optimize the series in collaboration with GSK and has been accepted by GSK
After successfully completing several rounds of discussions, Servier in France is now forming a partnership with Institut Pasteur Korea, utilizing one of our proprietary platforms in the area of metabolic disease to identify possible signaling pathway(s) and/or cellular target(s) of Servier’s small molecules.
On August 13, 2013, Institut Pasteur Korea signed a Master Research Agreement with DNDi for an in-depth collaboration beyond the previous partnership of sponsored research projects. The research will focus on neglected disease and will continue in 2015. DNDi is headquartered in Switzerland.
In addition to strategic partnerships with international organizations, Institut Pasteur Korea strives to support Korean public institutions, academia and pharma by providing access to its technology, as well as training and educating young Korean scientists. Important collaborations were established with:
Institut Pasteur Korea has set up a research station at Asan Medical Center to have closer access to clinicians and patient samples, and to explore research alliances in the field of oncology.
Natural compounds from Chungnam National University were tested in Institut Pasteur Korea’s innovative Leishmania and Chagas assays. Hits were identified and the results were published jointly by Institut Pasteur Korea and Chungnam National University.
The collaboration with Coway Co. Ltd. marked Institut Pasteur Korea’s first venture into the cosmetic industry. We performed visualization studies on live cells using the active ingredients in some of Coway’s products. We were able to visually demonstrate that Coway’s ingredients stimulate cell division.
A strategic alliance has been finalized on formation of a joint compound library.
Institut Pasteur Korea and Kyung Hee University have entered into a partnership. The university’s novel compounds will be incorporated into Institut Pasteur Korea’s compound library and tested in future screens performed at Institut Pasteur Korea. Any identified hits would be jointly developed by the two parties.
A cooperation agreement for a joint research program with Seoul National University was signed in November of 2012. The research involves testing several thousand proprietary, pure compounds from Seoul National University in Institut Pasteur Korea’s novel malaria assay to identify particular compounds active in the assay. The results were published jointly by Institut Pasteur Korea and Seoul National University.
Our research collaboration with Yonsei University on HBV has been extended due to its positive results and continues to be funded by our downstream partner, Sanofi.
An MOU was signed in January of 2015 to promote networking through exchange programs for researchers, and to perform collaborative research in the field of infectious disease using the innovative drug discovery technology platforms of Institut Pasteur Korea.
An MOU was signed that focuses on Institut Pasteur Korea’s technology and Yuhan’s compounds.